Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07466901) titled 'A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer' on March 9.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jin LI

Condition: Cervical Cancer Radical Surgery Adjuvant Therapy

Intervention: Drug: Camrelizumab

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: April 1, 2026

Target Sample Size: 30

Countries of Recruitment: China

To know more, visit htt...